ライフサイエンスコーパス: autoimmune hepatitis

1 viral causes (alcohol-induced liver disease, autoimmune hepatitis).

2 tivated T cells, and alleviate the damage of autoimmune hepatitis.

3 ession but led to spontaneous development of autoimmune hepatitis.

4 e, frequent allograft rejection, and de novo autoimmune hepatitis.

5 , resulting in suppression or stimulation of autoimmune hepatitis.

6 ly to do better with even rare diseases like autoimmune hepatitis.

7 n diagnosis, treatment, and understanding of autoimmune hepatitis.

8 in a model of ConA-mediated T cell-dependent autoimmune hepatitis.

9 rd opportunities to upgrade the treatment of autoimmune hepatitis.

10 ptic liver dysfunction or be associated with autoimmune hepatitis.

11 ccelerated hepatocyte damage in experimental autoimmune hepatitis.

12 sible consequences of corticosteroid-treated autoimmune hepatitis.

13 liver failure and fibrosis in two models of autoimmune hepatitis.

14 hepatitis B, primary biliary cirrhosis, and autoimmune hepatitis.

15 ic patients with posttransplantation de novo autoimmune hepatitis.

16 rine and prednisone similar to treatment for autoimmune hepatitis.

17 Bile duct changes are atypical of autoimmune hepatitis.

18 iral hepatitis, it is rarely associated with autoimmune hepatitis.

19 lure and side effects in treatment-dependent autoimmune hepatitis.

20 ckness-like disease, drug-induced lupus, and autoimmune hepatitis.

21 cyte damage, and thereby serve as a model of autoimmune hepatitis.

22 eviously undescribed histological finding in autoimmune hepatitis.

23 anti-dsDNA are common in ANA-positive type 1 autoimmune hepatitis.

24 is associated with genetic risk factors for autoimmune hepatitis.

25 odies to actin may miss patients with type 1 autoimmune hepatitis.

26 on treatment response and survival in type 1 autoimmune hepatitis.

27 en proposed as diagnostic markers for type 1 autoimmune hepatitis.

28 n of the similarity between the variants and autoimmune hepatitis.

29 tic approach to target adhesion molecules in autoimmune hepatitis.

30 ctors in regulating cellular immunity during autoimmune hepatitis.

31 hocyte populations in the liver and prevents autoimmune hepatitis.

32 therapy and represent autoantibody-negative autoimmune hepatitis.

33 osition affect the occurrence and outcome of autoimmune hepatitis.

34 liver regulatory DCs alleviated experimental autoimmune hepatitis.

35 %), acute hepatitis B virus infection (12%), autoimmune hepatitis (12%), and pregnancy-related ALF (2

36 ymorphism for CTLA-4 in patients with type 1 autoimmune hepatitis, 155 northern European Caucasoid pa

37 nction, of whom 5 have progressed to de novo autoimmune hepatitis, 2 to chronic rejection, one has pe

38 ation more often than patients with definite autoimmune hepatitis (33% vs. 8%, P = .05).

39 ycholic acid as adjunctive therapy in type 1 autoimmune hepatitis, 37 patients who had experienced tr

40 mune liver disease, 162 patients with type 1 autoimmune hepatitis, 37 patients with primary biliary c

41 apy as commonly as individuals with definite autoimmune hepatitis (75% vs. 64%, P = .5), and they res

42 and development of symptoms consistent with autoimmune hepatitis, a disease previously found to resu

43 roup (300 mg daclizumab HYP) died because of autoimmune hepatitis; a contributory role of daclizumab

44 uanine are promising treatments, and de-novo autoimmune hepatitis after liver transplantation suggest

45 ome may lead to diagnostic tests for de-novo autoimmune hepatitis after liver transplantation.

46 Hepatitis C virus can trigger autoimmune hepatitis after needlestick inoculation.

47 HBV) (+71), liver transplantation (+53), and autoimmune hepatitis (AIH) (+27).

48 52), chronic hepatitis C (CHC) (n = 30), and autoimmune hepatitis (AIH) (n = 8).

49 Autoimmune hepatitis (AIH) after liver transplantation (

50 Autoimmune hepatitis (AIH) after liver transplantation h

51 nduction and perpetuation of liver damage in autoimmune hepatitis (AIH) and autoimmune sclerosing cho

52 Autoimmune hepatitis (AIH) and cryptogenic chronic hepat

53 IF), and its receptor, CD74, was assessed in autoimmune hepatitis (AIH) and primary biliary cirrhosis

54 is the treatment of choice in patients with autoimmune hepatitis (AIH) and results in remission indu

55 autoimmune sclerosing cholangitis (ASC), and autoimmune hepatitis (AIH) are not well characterized.

56 e cholangitis were distinguished from type 1 autoimmune hepatitis (AIH) by lower serum levels of aspa

57 -induced liver injury (DILI) from idiopathic autoimmune hepatitis (AIH) can be challenging.

58 Autoimmune hepatitis (AIH) can lead to cirrhosis, hepati

59 A 62-year-old woman with type 1 autoimmune hepatitis (AIH) failed to sustain remission w

60 sus-host disease (GVHD) hepatitis resembling autoimmune hepatitis (AIH) has been reported after bone

61 The understanding of autoimmune hepatitis (AIH) has evolved in the past two d

62 mpact of ethnicity on the natural history of autoimmune hepatitis (AIH) has not been well characteriz

63 The diagnostic criteria for autoimmune hepatitis (AIH) have been codified by an inte

64 Diagnostic criteria for autoimmune hepatitis (AIH) have been created and revised

65 oluble liver antigen (tRNP((Ser)Sec)/SLA) in autoimmune hepatitis (AIH) have been investigated using

66 Patients with autoimmune hepatitis (AIH) have reduced numbers and func

67 ations about liver transplantation (LTX) for autoimmune hepatitis (AIH) have started to emerge, but m

68 Autoimmune hepatitis (AIH) in humans arises spontaneousl

69 Caucasian female, with a prior diagnosis of autoimmune hepatitis (AIH) in remission, presented with

70 re described, who went on to develop de novo autoimmune hepatitis (AIH) in the transplanted liver.

71 Autoimmune hepatitis (AIH) is a chronic inflammatory dis

72 Autoimmune hepatitis (AIH) is a chronic inflammatory liv

73 Autoimmune hepatitis (AIH) is a chronic, progressive hep

74 Autoimmune hepatitis (AIH) is an important cause of seve

75 Autoimmune hepatitis (AIH) is an uncommon autoimmune liv

76 Susceptibility to autoimmune hepatitis (AIH) is associated with the HLA A1

77 Autoimmune hepatitis (AIH) is characterized by a loss of

78 Autoimmune hepatitis (AIH) is characterized by chronic i

79 Autoimmune hepatitis (AIH) is defined as a chronic liver

80 en reported in early childhood, while type 2 autoimmune hepatitis (AIH) is eminently a paediatric dis

81 Genetic involvement in type 1 autoimmune hepatitis (AIH) is indicated by a marked fema

82 Autoimmune hepatitis (AIH) is known as a T cell-mediated

83 The etiopathogenesis of autoimmune hepatitis (AIH) remains poorly understood.

84 Autoimmune hepatitis (AIH) typically responds to treatme

85 epresent an immune intervention candidate in autoimmune hepatitis (AIH), a condition characterized by

86 of autoantibodies vary during the course of autoimmune hepatitis (AIH), and some autoantibodies have

87 BACKGROUND/AIM: It remains uncertain whether autoimmune hepatitis (AIH), as an original indication fo

88 prine (AZA) is used to maintain remission in autoimmune hepatitis (AIH), but up to 18% of patients ar

89 enesis of autoimmune liver diseases, such as autoimmune hepatitis (AIH), has been hampered by a lack

90 epatitis, the histological lesion typical of autoimmune hepatitis (AIH), is composed of CD4 and CD8 T

91 In autoimmune hepatitis (AIH), liver-damaging CD4 T cell re

92 ata on the mortality and cancer incidence of autoimmune hepatitis (AIH), primary biliary cirrhosis (P

93 rare complication of cirrhosis secondary to autoimmune hepatitis (AIH), yet the true incidence remai

94 oms of certain autoimmune diseases including autoimmune hepatitis (AIH).

95 re defective numerically and functionally in autoimmune hepatitis (AIH).

96 ulfilled the diagnostic criteria for de novo autoimmune hepatitis (AIH).

97 tiple organs, and 20% of patients develop an autoimmune hepatitis (AIH).

98 ), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH).

99 l and immunological characteristics of human autoimmune hepatitis (AIH).

100 les associated with susceptibility to type 1 autoimmune hepatitis also influence its clinical feature

101 to treat inflammatory liver diseases such as autoimmune hepatitis and alcoholic hepatitis.

102 ch patients have findings indicative of both autoimmune hepatitis and another disorder (overlap syndr

103 IH, we identified susceptibility factors for autoimmune hepatitis and attempted to restore immunologi

104 in autoimmune liver disease (AILD; including autoimmune hepatitis and autoimmune sclerosing cholangit

105 ace, and it can be targeted by antibodies in autoimmune hepatitis and chronic hepatitis C.

106 that improve the diagnosis and treatment of autoimmune hepatitis and extend the understanding of its

107 that improve the diagnosis and treatment of autoimmune hepatitis and extend understanding of its pat

108 It is also linked to two human diseases, autoimmune hepatitis and glutamate formiminotransferase

109 tosis, is upregulated and activated in human autoimmune hepatitis and in a murine model of inflammati

110 diseases primary sclerosing cholangitis and autoimmune hepatitis and inflammatory bowel disease, we

111 Azathioprine is commonly prescribed for autoimmune hepatitis and inflammatory bowel disease.

112 chronic hepatitis is indistinguishable from autoimmune hepatitis and it responds as well to corticos

113 the bases for the classification of probable autoimmune hepatitis and its clinical importance.

114 llele is more common in patients with type 1 autoimmune hepatitis and may represent a second suscepti

115 ognized by autoantibodies from patients with autoimmune hepatitis and on the binding of thin vimentin

116 that improve the diagnosis and treatment of autoimmune hepatitis and presage new drug and molecular

117 Variant forms, including syndromes with autoimmune hepatitis and primary biliary cirrhosis (7%)

118 Individuals with autoimmune hepatitis and primary biliary cirrhosis enter

119 Overlap syndromes include combinations of autoimmune hepatitis and primary biliary cirrhosis, prim

120 an be effective in patients with features of autoimmune hepatitis and primary biliary cirrhosis.

121 Patients with autoimmune hepatitis and primary sclerosing cholangitis

122 and they responded better than patients with autoimmune hepatitis and primary sclerosing cholangitis

123 that improve the diagnosis and treatment of autoimmune hepatitis and suggest new drug and molecular

124 We report a case of autoimmune hepatitis and the subsequent, rarely occurrin

125 esonide in patients with treatment-dependent autoimmune hepatitis and to determine if efficacy and sa

126 cientist can contribute to the maturation of autoimmune hepatitis and to illustrate the principles of

127 with primary sclerosing cholangitis, 16 with autoimmune hepatitis, and 40 with systemic lupus erythem

128 ts of Fas ligand are abnormally increased in autoimmune hepatitis, and apoptotic dysfunction may cont

129 Pregnancy is not contraindicated in autoimmune hepatitis, and cyclosporine may be effective

130 ease such as steatohepatitis, iron overload, autoimmune hepatitis, and drug-induced injury.

131 advances promise to improve the treatment of autoimmune hepatitis, and investigations of these advanc

132 inical and laboratory features that resemble autoimmune hepatitis, and it may respond initially to co

133 Hepatitis B virus, hepatitis C virus, autoimmune hepatitis, and nonalcoholic fatty liver disea

134 up contained mainly alcoholic liver disease, autoimmune hepatitis, and primary biliary cirrhosis.

135 satisfied international scoring criteria for autoimmune hepatitis, and the findings were correlated w

136 ed that biliary changes can occur in classic autoimmune hepatitis, and they are not associated with d

137 ibodies lack sensitivity and specificity for autoimmune hepatitis, and they have diverse antigen spec

138 ecrosis is within the histologic spectrum of autoimmune hepatitis, and variant syndromes may be refra

139 ochromatosis, alpha1-antitrypsin deficiency, autoimmune hepatitis, and Wilson's disease.

140 vation-induced cell death may be impaired in autoimmune hepatitis, and, in contrast to budesonide, my

141 Variant forms of autoimmune hepatitis are common.

142 The incidence and prevalence of autoimmune hepatitis are greater than expected among whi

143 Outcomes of autoimmune hepatitis are poor in our setting but access

144 Identifying autoimmune hepatitis as the etiology of acute liver fail

145 ry liver disease states, including viral and autoimmune hepatitis as well as liver allograft rejectio

146 s, 44 patients transplanted for cryptogenic, autoimmune, hepatitis B, or cholestatic liver disease an

147 tinguished from those designated as definite autoimmune hepatitis by male sex, concurrent immune dise

148 Twenty-seven patients designated as probable autoimmune hepatitis by one system were designated as de

149 The designation of probable autoimmune hepatitis by the international scoring system

150 is by one system were designated as definite autoimmune hepatitis by the other system.

151 enteen patients (9%) were graded as probable autoimmune hepatitis by the revised original scoring sys

152 rimary sclerosing cholangitis (PSC), chronic autoimmune hepatitis (CAH), systemic lupus erythematosus

153 Autoimmune hepatitis can affect diverse ethnic groups, a

154 De-novo autoimmune hepatitis can occur in adults and children af

155 Autoimmune hepatitis can present as acute or chronic hep

156 Autoimmune hepatitis can present as an acute or fulminan

157 The diagnostic scoring systems for autoimmune hepatitis categorize some patients as having

158 Autoimmune hepatitis causes chronic hepatitis and often

159 he criteria established by the International Autoimmune Hepatitis Club.

160 Clinical phenotypes of autoimmune hepatitis commonly include rheumatic manifest

161 Autoimmune hepatitis commonly relapses after corticoster

162 De novo autoimmune hepatitis, consisting of histological chronic

163 s (hepatitis B virus, hepatitis C virus, and autoimmune hepatitis) contain increased numbers of PD-1-

164 henotypes: nontolerant (n = 18) with de novo autoimmune hepatitis (DAIH) and/or late acute cellular r

165 we show that Tregs of patients with de novo autoimmune hepatitis (dAIH) display increased frequencie

166 of treatment failure in patients with type 1 autoimmune hepatitis, define features associated with it

167 n of the clinically useful short form of the autoimmune hepatitis diagnostic scoring system; accumula

168 orticosteroids improve survival in fulminant autoimmune hepatitis, drug-induced, or indeterminate ALF

169 that clarify the rheumatic manifestations of autoimmune hepatitis, elucidate shared pathogenic pathwa

170 Autoimmune hepatitis emerged during an era when concepts

171 Autoimmune hepatitis exemplifies an evolutionary process

172 Subjects with obesity, type 2 diabetes, and autoimmune hepatitis exhibited lower levels of unmethyla

173 een created and revised by the International Autoimmune Hepatitis Group (IAIHG).

174 A clinical subcommittee of the International Autoimmune Hepatitis Group reviewed current management d

175 International Autoimmune Hepatitis Group scores were calculated.

176 On the International Autoimmune Hepatitis Group scoring system, five patients

177 ease, and the formation of the International Autoimmune Hepatitis Group standardized the diagnosis, i

178 Autoimmune hepatitis has a global distribution and diver

179 Autoimmune hepatitis has a global distribution, and its

180 Susceptibility for type 1 autoimmune hepatitis has been associated with the major

181 Autoimmune hepatitis has clinical manifestations, serolo

182 Autoimmune hepatitis has diverse presentations and manif

183 Patients with type 2 autoimmune hepatitis have different HLA frequencies than

184 y cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, hepatitis B virus, and hepatitis C

185 In contrast to classical autoimmune hepatitis, histological features of AI-ALF pr

186 s (ANA) failed to establish the diagnosis of autoimmune hepatitis in 5 patients.

187 in 16.3%, chronic viral hepatitis in 30.6%, autoimmune hepatitis in 8.2%, and primary biliary cirrho

188 DRB1*1301 is associated with autoimmune hepatitis in Brazil, especially among childre

189 Autoimmune hepatitis in children may be associated with

190 mary sclerosing cholangitis may overlap with autoimmune hepatitis in some cases, although the real pr

191 sclerosing cholangitis in children can mimic autoimmune hepatitis in the absence of inflammatory bowe

192 eactivity, although such knowledge in type 2 autoimmune hepatitis, in which the known autoantigen is

193 lucocorticoids in the long-term treatment of autoimmune hepatitis, including azathioprine, a purine a

194 Smad3 signaling in an experimental model of autoimmune hepatitis induced by concanavalin A (ConA), a

195 hyma but not in lymphoid cells protects from autoimmune hepatitis induced by mitogen concanavalin A (

196 Autoimmune hepatitis initially had to be distinguished f

197 Autoimmune hepatitis is a disease of the hepatic parench

198 Autoimmune hepatitis is as virulent in the elderly as in

199 omposite histological pattern that resembles autoimmune hepatitis is associated with greater immunore

200 In common with many autoimmune diseases, autoimmune hepatitis is associated with non-organ-specif

201 Autoimmune hepatitis is classically a disease of young w

202 that liver damage in this model of fulminant autoimmune hepatitis is driven by CD4(+) T cell producti

203 Although the treatment of choice for autoimmune hepatitis is glucocorticoids, their side effe

204 Genetic susceptibility to type 1 autoimmune hepatitis is indicated by a preponderance of

205 The classical histological finding in autoimmune hepatitis is lymphocytic infiltration of the

206 nts with chronic hepatitis, the diagnosis of autoimmune hepatitis is made on the basis of increased g

207 tures that mimic other diseases, such as the autoimmune hepatitis-like syndrome that may follow liver

208 re not abnormal universally in patients with autoimmune hepatitis, liver biopsy remains an important

209 Autoimmune hepatitis may fail to respond to corticostero

210 Children with autoimmune hepatitis may have abnormal cholangiogram res

211 Recurrent or de novo autoimmune hepatitis must be considered as a cause of gr

212 Autoimmune hepatitis must be considered in all patients

213 ients with chronic viral hepatitis (n = 22), autoimmune hepatitis (n = 10), and obstructive jaundice

214 s C (n=16), cryptogenic cirrhosis (n=2), and autoimmune hepatitis (n=1).

215 s (n= 19), sclerosing cholangitis (n=6), and autoimmune hepatitis (n=5) (group II).

216 Autoimmune hepatitis occurred in patients aged 18-30 yea

217 None of the 15 controls developed de novo autoimmune hepatitis or any other form of persistent gra

218 nsplanted at experienced centers with either autoimmune hepatitis or cholestatic liver disease had si

219 on, nonsteroidal anti-inflammatory drugs, or autoimmune hepatitis) or patients without acute liver fa

220 Retransplant recipients, patients with autoimmune hepatitis, or status 1 or 2A patients were ex

221 inconsistent with the classic definition of autoimmune hepatitis (outlier syndromes).

222 e diseases, and/or subsequent development of autoimmune hepatitis overlap syndrome.

223 Presence of autoimmune hepatitis overlapping with PSC (P =.2) or med

224 Autoimmune hepatitis overlapping with PSC was present in

225 DR-locus mismatch increased recurrence of autoimmune hepatitis (P = 0.01, HR = 4.2) and primary bi

226 lysis were more likely to have the classical autoimmune hepatitis phenotype (female predominance [72%

227 t polycystic livers and might also influence autoimmune hepatitis, primary biliary cirrhosis, and cho

228 xist with autoimmune liver disorders such as autoimmune hepatitis, primary biliary cirrhosis, and pri

229 Patients with autoimmune hepatitis, primary sclerosing cholangitis, an

230 e reviews the relevant literature of de novo autoimmune hepatitis, recurrent autoimmune hepatitis, re

231 e of de novo autoimmune hepatitis, recurrent autoimmune hepatitis, recurrent primary sclerosing chola

232 atitis (score of 10-15) and one had definite autoimmune hepatitis (score > 15) at the onset of graft

233 p scoring system, five patients had probable autoimmune hepatitis (score of 10-15) and one had defini

234 n antinuclear antibody (ANA)-positive type 1 autoimmune hepatitis, sera from 53 patients were tested

235 Autoimmune hepatitis should be considered in all patient

236 , the ulcers completely healed, and with the autoimmune hepatitis still in remission.

237 Progress in type 1 autoimmune hepatitis still requires knowledge of a disea

238 taining in liver biopsies from patients with autoimmune hepatitis suggests a role for MLKL in this di

239 hemochromatosis gene occurs more commonly in autoimmune hepatitis than in normal subjects, but it is

240 occurs more commonly in patients with type 1 autoimmune hepatitis than in normal subjects; it is asso

241 Autoimmune hepatitis type 2 (AIH-2) is a severe organ-sp

242 chrome P450IID6 (CYP2D6), the autoantigen of autoimmune hepatitis type 2 (AIH-2), are permitted by a

243 chrome P450IID6 (CYP2D6), the autoantigen of autoimmune hepatitis type 2 (AIH-2), are permitted by a

244 time, the significance of Smad3 signaling in autoimmune hepatitis, underlining the control of Smad3-d

245 et al. demonstrate that, in a mouse model of autoimmune hepatitis, viral infections not only trigger

246 Autoimmune hepatitis was associated with an increased ri

247 Female sex and autoimmune hepatitis were associated with an increased r

248 onsequences of these polymorphisms in type 1 autoimmune hepatitis were determined.

249 e North American adults with definite type 1 autoimmune hepatitis were grouped according to age at pr

250 Diagnostic scores for autoimmune hepatitis were lower in patients with bile du

251 Sera from 99 patients with type 1 autoimmune hepatitis were tested.

252 ry tests in problematic patients with type 1 autoimmune hepatitis when administered adjunctively for

253 Our data show that symptoms of autoimmune hepatitis, which are responsive to the classi

254 We report a patient with autoimmune hepatitis who developed severe small-bowel vi

255 We report 3 patients with autoimmune hepatitis who either could not tolerate or fa